...80% of high‐income countries are not on track to meet the WHO targets, and it is estimated that at the current pace of implementation, 67% will not reach elimination targets before 2050, if ever. Slow scale‐up will only serve to perpetuate the epidemic over decades and the major health gains associated with HCV treatment will be thwarted. ...the momentum that has built in response to the WHO call to action will be squandered as other important health, social and environmental needs inevitably eclipse this cause. ...significant savings in health costs are projected. There are many parallel harm reduction innovations emerging such as supervised injection sites , prescription heroin , and even needle and opioid dispensing machines that if scaled up and paired with elimination efforts could reduce overdoses and help disrupt HCV transmission.